US 4197307A
· Gallay et al.
· 1980
[cited by applicant]
US 5114938A
· Lindner et al.
· 1992
[cited by applicant]
US 6787652B1
· Dow et al.
· 2004
[cited by applicant]
US 7807674B2
· Haynes et al.
· 2010
[cited by applicant]
US 8153624B2
· Genin et al.
· 2012
[cited by applicant]
US 8785408B2
· Feinstein et al.
· 2014
[cited by applicant]
US 8791266B2
· Kawata et al.
· 2014
[cited by applicant]
US 20030078288A1
· Haning et al.
· 2003
[cited by applicant]
US 20100004271A1
· Garcia Collazo et al.
· 2010
[cited by applicant]
US 20200054589A1
· Noel et al.
· 2020
[cited by applicant]
US 20200397798A1
· Mohan et al.
· 2020
[cited by applicant]
US 20210379040A1
· Fenaux et al.
· 2021
[cited by applicant]
US 20210379043A1
· Fenaux et al.
· 2021
[cited by applicant]
US 20220135540A1
· Sweetana et al.
· 2022
[cited by applicant]
US 20220348561A1
· Kirschberg et al.
· 2022
[cited by applicant]
US 20230241071A1
· Fenaux et al.
· 2023
[cited by applicant]
US 20240000765A1
· Fenaux et al.
· 2024
[cited by applicant]
US 20240059682A1
· Kirschberg et al.
· 2024
[cited by applicant]
US 20240156826A1
· Taub
· 2024
[cited by applicant]
US 20240239761A1
· Zhang et al.
· 2024
[cited by applicant]
US 20240293416A1
· Jones et al.
· 2024
[cited by applicant]
US 20240316025A1
· Fenaux et al.
· 2024
[cited by applicant]
CN 101228135A
· 2008
[cited by applicant]
CN 102898377A
· 2013
[cited by applicant]
CN 103130723A
· 2013
[cited by applicant]
CN 105477636A
· 2016
[cited by applicant]
CN 110167557A
· 2019
[cited by applicant]
CN 111320609A
· 2020
[cited by applicant]
CN 111484481A
· 2020
[cited by applicant]
CN 111909137A
· 2020
[cited by applicant]
CN 114437034A
· 2022
[cited by applicant]
EP 1471049A1
· 2004
[cited by applicant]
EP 3437659A1
· 2019
[cited by applicant]
EP 3807267A1
· 2021
[cited by applicant]
IN 202047050376A
· 2020
[cited by applicant]
JP H02225483A
· 1990
[cited by applicant]
JP 2001114768A
· 2001
[cited by applicant]
JP 2004517851A
· 2004
[cited by applicant]
JP 2007512314A
· 2007
[cited by applicant]
JP 2009501759A
· 2009
[cited by applicant]
JP 2011114768A
· 2011
[cited by applicant]
JP 2011528007A
· 2011
[cited by applicant]
JP 2017525740A
· 2017
[cited by applicant]
JP 2021531325A
· 2021
[cited by applicant]
RU 2668960C2
· 2018
[cited by applicant]
WO WO0198256A1
· 2001
[cited by applicant]
WO WO03064369A1
· 2003
[cited by applicant]
WO WO03094845A2
· 2003
[cited by applicant]
WO WO2007003419A1
· 2007
[cited by applicant]
WO WO2007009913A1
· 2007
[cited by applicant]
WO WO2007128492A1
· 2007
[cited by applicant]
WO WO2007134864A1
· 2007
[cited by applicant]
WO WO2009012125A1
· 2009
[cited by applicant]
WO WO2009037172A1
· 2009
[cited by applicant]
WO WO2010006962A1
· 2010
[cited by applicant]
WO WO2010122980A1
· 2010
[cited by applicant]
WO WO2011038207A1
· 2011
[cited by applicant]
WO WO2014043706A1
· 2014
[cited by applicant]
WO WO2016036873A1
· 2016
[cited by applicant]
WO WO2017167935A1
· 2017
[cited by applicant]
WO WO2017170434A1
· 2017
[cited by applicant]
WO WO2018027892A1
· 2018
[cited by applicant]
WO WO2018028517A1
· 2018
[cited by applicant]
WO WO2018073154A1
· 2018
[cited by applicant]
WO WO2018075650A1
· 2018
[cited by applicant]
WO WO2018103624A1
· 2018
[cited by applicant]
WO WO2018153933A1
· 2018
[cited by applicant]
WO WO2018167103A1
· 2018
[cited by applicant]
WO WO2018170173A1
· 2018
[cited by applicant]
WO WO2018193006A1
· 2018
[cited by applicant]
WO WO2018193007A1
· 2018
[cited by applicant]
WO WO2018208707A1
· 2018
[cited by applicant]
WO WO2019023245A1
· 2019
[cited by applicant]
WO WO2019038456A1
· 2019
[cited by applicant]
WO WO2019053233A1
· 2019
[cited by applicant]
WO WO2019053235A1
· 2019
[cited by applicant]
WO WO2019094777A1
· 2019
[cited by applicant]
WO WO2019144835A1
· 2019
[cited by applicant]
WO WO2019240938A1
· 2019
[cited by applicant]
WO WO2020041741A1
· 2020
[cited by applicant]
WO WO2020042114A1
· 2020
[cited by applicant]
WO WO2020061086A2
· 2020
[cited by applicant]
WO WO2020061114A1
· 2020
[cited by applicant]
WO WO2020073974A1
· 2020
[cited by applicant]
WO WO2020077123A1
· 2020
[cited by applicant]
WO WO2020123827A1
· 2020
[cited by applicant]
WO WO2020131578A2
· 2020
[cited by applicant]
WO WO2020169069A1
· 2020
[cited by applicant]
WO WO2020227549A1
· 2020
[cited by applicant]
WO WO2020239076A1
· 2020
[cited by applicant]
WO WO2021014350A1
· 2021
[cited by applicant]
WO WO2021041237A1
· 2021
[cited by applicant]
WO WO2021050945A1
· 2021
[cited by applicant]
WO WO2021121210A1
· 2021
[cited by applicant]
WO WO2021231644A1
· 2021
[cited by applicant]
WO WO2021231646A1
· 2021
[cited by applicant]
WO WO2022152770A1
· 2022
[cited by applicant]
WO WO2022187403A1
· 2022
[cited by applicant]
WO WO2023083288A1
· 2023
[cited by applicant]
WO WO2023086561A1
· 2023
[cited by applicant]
WO WO2023220404A1
· 2023
[cited by applicant]
Bashir, M., et al., “Liver vol. Reduction in Resmetirom Treated Non-Cirrhotic and Cirrhotic NASH Patients,” Hepatology, Oct. 2021, vol. 74, No. 1 (Supplement), pp. 1142A-1143A.
[cited by applicant]
Co-pending U.S. Appl. No. 18/818,705, inventors Kirschberg; Thorsten A. et al., filed Aug. 29, 2024.
[cited by applicant]
Dennis, A., et al., “Correlations Between MRI Biomarkers PDFF and cT1 with Histopathological Features on Non-Alcoholic Steatohepatitis,” Frontiers in Endocrinology, Jan. 2021, vol. 11, Article 575843, 10 pages.
[cited by applicant]
Extended European Search Report and Search Opinion, dated Apr. 2, 2024, for European Patent Application No. 21803928.7, 11 pages.
[cited by applicant]
Gallup. Americans' Average Weight Holds Steady in 2020, Jan. 4, 2021, Retrieved from the Internet on Sep. 27, 2023, https://news.gallup.com/poll/328241/americans-average-weight-holds-steady-2020.aspx, 9 pages.
[cited by applicant]
Harrison, S. A., et al., “A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis,” The New England Journal of Medicine, Feb. 8, 2024, vol. 390, No. 6, pp. 497-509.
[cited by applicant]
Harrison, S. A., et al., “Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial,” Nature Medicine, Nov. 2023, vol. 29, 2919-2928, including additional material, 19…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/049690 mailed May 23, 2024, 12 pages.
[cited by applicant]
International Preliminary Report on Patentability, mailed May 23, 2024, for International Application No. PCT/CN2022/131297, 7 pages.
[cited by applicant]
Kirschberg, T., et al., “TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent m…
[cited by applicant]
Loomba, R., et al., Relationship of Non-Invasive Measures with Histological Response in Patients with NonAlcoholic Steatohepatitis and Fibrosis: 52-Week Data from the Phase 3 Maestro-NASH Trial, Hepatology, 2023, 78 (Su…
[cited by applicant]
Noureddin, M., et al., “5000 | Topline Results from a 12-Week Phase 2a Trial (Duet) Evaluating Tern-501, A Highly Selective Thyroid Hormone Receptor (THR) Beta Agonist, Either as Monotherapy or in Combination with TERN-…
[cited by applicant]
Noureddin, M., et al., “Head-to-Head Comparison of Fast, Mast, MEFIB and cT1 in Identifying At-Risk NASH Patients in a Low-Prevalence Population,” Hepatology, 2023, 78(Supplement 1):S1-S2154, pp. S806-S810, Abstract 205…
[cited by applicant]
Rich, N. E., et al., “Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis,” Clinical Gastroenterology and Hepa…
[cited by applicant]
Rinella, M. E., et al., “AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease,” Hepatology 2023, 77, 1797-1835.
[cited by applicant]
Stine, J. G., et al., “Change in MRI-PDFF and Histologic Response in Patients with Non-alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis,” Clinical Gastroenterology and Hepatology 2021, vol. 19, No. 11, 2…
[cited by applicant]
Sumida, Y., et al., “Current and new pharmacotherapy options for non-alcoholic steatohepatitis,” Expert Opinion on Pharmacotherapy, vol. 21, No. 8, Apr. 1, 2020, pp. 953-967, DOI: 10.1080/14656566.2020.1744564.
[cited by applicant]
Ashburner M., et al., “Gene Ontology: Tool For The Unification Of Biology. The Gene Ontology Consortium,” Nature Genetics, May 2000, vol. 25, pp. 25-29.
[cited by applicant]
Basnak, I. et al. (1975). “Synthesis of 5-cyclopropyl-6-azauracil,” Collect. Czech Chem. Commun. 40(4):1038-1042.
[cited by applicant]
Baxter, J. D. et al., “Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes,” Nature Reviews Drug Discovery, vol. 8, No. 4, pp. 308-320 (Apr. 2009).
[cited by applicant]
Belikov, V.G, “Pharmaceutical Chemistry. Chapter 2.6 Relationship between the chemical structure, properties of substances and their effect on the body”, MEDpress-inform (2007); pp. 27-29; 14 pages with English translat…
[cited by applicant]
Berry, M. J., et al., “Thyroid hormone regulates type I deiodinase messenger RNA in rat liver,” Molecular Endocrinology, 1990, 4:743-748.
[cited by applicant]
Brecher, J., “Graphical Representation of Stereochemical Configuration (IUPAC Recommendations 2006),” Pure and Appl. Chem. 78(10):1897-1970 (2006).
[cited by applicant]
Chen, H.C. et al. (Nov. 13-16, 2020). MET409, an Optimized Sustained FXR Agonist, Was Safe and Well-Tolerated in a 14-Day Phase 1 Study in Healthy Subjects, Me0.tacrine, 1 page, Poster presented at Poster presentation a…
[cited by applicant]
Chung D., et al., “Pharmacokinetics Of Two Oral Formulations Of Liver-directed, Nonsteroidal Farnesoid X-Receptor Agonist Tern-101 In Healhy Volunteers,” Terns Pharmaceutical, Inc., Poster presented at Paris NASH Meetin…
[cited by applicant]
Dermer, G.B., “Another Anniversary for the War on Cancer,” Bio/Technology, 12:320, 1 page (Mar. 1994).
[cited by applicant]
Dufour J-F., et al., “Combination Therapy For Non-Alcoholic Steatohepatitis: Rationale, Opportunities And Challenges,” Gut, 69(10):1877-1884 (2020).
[cited by applicant]
Dunkel, P. et al., “Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey,” Expert Opinion on Therapeutic Patents, Jun. 2011, vol. 21, No. 9, pp. 1453-1471, doi: 10.1517/13543776.2011.594040.
[cited by applicant]
Erion, M.D., “Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index,” PNAS, Sep. 25, 2007, 104(39), 15490-15495.
[cited by applicant]
Extended European Search Report and Search Opinion for Application No. 19870196.3, mailed on May 18, 2022, 5 pages.
[cited by applicant]
Extended European Search Report and Search Opinion for European Application No. 19852050.4, mailed Mar. 22, 2022, 7 Pages.
[cited by applicant]
Extended European Search Report and Search Opinion, mailed Aug. 17, 2023, for European Patent Application No. 20863146.5, 7 pages.
[cited by applicant]
Extended European Search Report and Search Opinion, mailed Jul. 6, 2022, for European Application No. 19896475.1 (8 total pages).
[cited by applicant]
Extended European Search Report and Search Opinion, mailed Mar. 30, 2023, for European Application No. 20856291.8 (8 total pages).
[cited by applicant]
Fiorucci, S., et al., “Future trends in the treatment of nonalcoholic steatohepatitis,” Pharmacological Research, Jul. 2018, vol. 134, pp. 289-298, doi: 10.1016/J.PHRS.2018.07.014.
[cited by applicant]
Freshney R.I., et al., “Culture of Animal Cells,” A Manual of Basic Technique, 1983, Alan R. Liss, Inc., New York, p. 4 and pp. 129-133 (9 total pages).
[cited by applicant]
Gene Ontology Consortium, Creating the Gene Ontology Resource: Design and Implementation. Genome Research 11: 1425-1433 (2001).
[cited by applicant]
Grover, G. J., et al., Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine, Endocrinology, vol. 145, No. …
[cited by applicant]
Han C.Y., “Update on FXR Biology: Promising Therapeutic Target?,” International Journal of Molecular Sciences, Jul. 16, 2018, vol. 19, No. 2069, 25 pages.
[cited by applicant]
Hansen, H. H., et al., “Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis,” BMC Gastroenterology (2020), 20:210, pp. 1-12, https://doi.org/10.1186/s12876-020-01356-2.
[cited by applicant]
Hennessey, J. V., et al., “The emergence of levothyroxine as a treatment for hypothyroidism,” Endocrine, 2017, 55: 6-18, DOI: 10.1007/s12020-016-1199-8.
[cited by applicant]
Hill, S. R. Jr., S et al. (1960). “The Metabolic Effects of the Acetic and Propionic Acid Analogs of Thyroxine and Triiodothyronine,” J Clin. Invest. (39):523-533.
[cited by applicant]
Ichiki, T., et al., “Thyroid Hormone and Vascular Remodeling,” Journal of Atherosclerosis and Thrombosis, 2016, vol. 23, No. 3, pp. 266-275.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/CN2018/103349, mailed Mar. 11, 2021, 7 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2008/069719, mailed Jan. 19, 2010, 7 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/047968, mailed Mar. 11, 2021, 7 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/055689, mailed Apr. 22, 2021, 9 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/066013, mailed Jun. 24, 2021, 6 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/047467, mailed Mar. 3, 2022, 9 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/050497, mailed Mar. 24, 2022, 7 Pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/018575, mailed Sep. 14, 2023, 18 pages.
[cited by applicant]
International Preliminary Report on Patentability, mailed Nov. 24, 2022, for International Application No. PCT/US2021/032085 (12 total pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CN2018/103349, mailed Jun. 5, 2019, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CN2022/131297, mailed on Feb. 10, 2023, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2008/069719, mailed Nov. 6, 2008, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/047968, mailed Nov. 21, 2019, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/055689, mailed Jan. 23, 2020, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/066013, mailed Feb. 28, 2020, 8 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/047467, mailed Jan. 15, 2021, 12 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/050497, mailed Dec. 8, 2020, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/059522, mailed Feb. 5, 2021, 9 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/032085, mailed Sep. 30, 2021, 17 Pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/049690, mailed Mar. 16, 2023, 21 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Aug. 2, 2023, for International Application No. PCT/US2023/022093, 8 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed May 23, 2022, for International Application No. PCT/US2022/018575 (21 total pages).
[cited by applicant]
Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee, mailed Jul. 6, 2021, for International Application No. PCT/US2021/032083 (3 total pages).
[cited by applicant]
Invitation to Pay Additional Fees, mailed Jul. 6, 2021, for International Application No. PCT/US2021/032085, 3 pages.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Nov. 21, 2019, for International Application No. PCT/US2019/055689, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Oct. 4, 2020, for International Application No. PCT/US2020/047467, 2 pages.
[cited by applicant]
Jones C., et al., “Combination of TERN-101, a Farnesoid X Receptor Agonist, and TERN-501, a Selective Agonist of Thyroid Hormone Receptor Beta, Reduces Activation of Inflammatory and Fibrotic Gene Pathways in a Mouse Mo…
[cited by applicant]
Jones, C., et al., EASL, Aug. 28, 2020, Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in…
[cited by applicant]
Jones, C., et al., Single doses of the THR-B agonist TERN-501 are well tolerated and result in dose-dependent changes in LDL cholesterol and sex hormone binding globulin in a first-in-human clinical trial, AASLD, Nov. 1…
[cited by applicant]
Kawamata, Y., et al. “AG protein-coupled receptor responsive to bile acids”, The Journal of Biological Chemistry, 278(11):9435-9440 (Mar. 2003).
[cited by applicant]
Kelly, M. J., et al., “Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6- carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Re…
[cited by applicant]
Kim D., et al., “Critical Roles of the Histone Methyltransferase MLL4/KMT2D in Murine Hepatic Steatosis Directed by ABL1 and PPARgamma2,” Cell Reports, 2016, vol. 17(6), pp. 1671-1682, DOI: 10.1016/j.celrep.2016.10.023.
[cited by applicant]
Kirschberg, T., et al., EASL, Aug. 29, 2020, “TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated …
[cited by applicant]
Klein, I et al., “Cardiovascular Involvement in General Medical Conditions, Thyroid Disease and the Heart,” Circulation, Oct. 9, 2007, 116:1725-1735.
[cited by applicant]
Kleiner, D. E., et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, Jun. 2005, 41(6):1313-1321.
[cited by applicant]
Klucher, K., et al., EASL, Aug. 29, 2020, Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatit…
[cited by applicant]
Kogler, M., “Synthesis and Evaluation of 6-aza-2′-deoxyuridine Monophosphate Analogs as Inhibitors pf Thymidylate Synthases, and as Substrates or Inhibitors of Thymidine Monophosphate Kinase in Mycobacterium tuberculosi…
[cited by applicant]
Kowalik et al., “Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease,” Frontiers in Endocrinology, vol. 9, Article 382, pp. 1-11 (Jul. 2018).
[cited by applicant]
Krchnak, V. et al., “Novel Pyrimidine Derivatives, Reactions and Ultraviolet Spectra,” Collection Czechoslov. Chem. Commun. 1975, vol. 40, pp. 1396-1402.
[cited by applicant]
Kremoser C., “Fxr Agonists for NASH: How Are They Different And What Difference Do They Make?,” Journal of Hepatology 2021, vol. 75, pp. 12-15.
[cited by applicant]
Liver Meeting Digital Experience 2020, Oct. 14, 2020, https://www.ternspharma.com/1 0-14-20- terns-to-present-positive-data-on-single-agend-and-combo-nash-at-liver-meeting-exp-2020, 3 pages.
[cited by applicant]
Loomba, R., et al., “Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data,” Alimentary Pharmacology and The…
[cited by applicant]
Nelson, C. H., et al., Multiple Doses of Thyroid Hormone Receptor-Beta Agonist TERN-501 were Well-Tolerated and Resulted in Significant Dose-Dependent Changes in Serum Lipids and Sex Hormone Binding Globulin in a First-…
[cited by applicant]
Nelson, C. H., et al., Thyroid Hormone Beta Receptor Agonist Tern-501 Demonstrates Dose- And Exposure-Dependent Increases In Sex Hormone Binding Globulin With Associated Decreases In Atherogenic Lipids In Healthy Subjec…
[cited by applicant]
Nelson, R. H., “Hyperlipidemia as a risk factor for cardiovascular disease,” Prim Care Clin Office Pract 40 (2013) 195-211, http://dx.doi.org/10.1016/j.pop.2012.11.003.
[cited by applicant]
Obach R.S., et al., “The Prediction Of Human Pharmacokinetic Parameters From Preclinical And In Vitro Metabolism Data,” Journal of Pharmacology and Experimental Therapeutics, 1997, vol. 283, No. 1, pp. 46-58.
[cited by applicant]
Pagadala, M. R, et al., “Prevalence of hypothyroidism in nonalcoholic fatty liver disease,” Digestive Diseases and Sciences, 2012, 57:528-534, DOI 10.1007/s10620-011-2006-2.
[cited by applicant]
Pubchem (Jan. 12, 2016). “4-(1,2,4-Benzotriazin-3-Yloxy)-N-Methylaniline,” CID: 103204817, 7 pages.
[cited by applicant]
Schwimmer, J. B., et al., “Prevalence Of Fatty Liver In Children And Adolescents,” Pediatrics, Oct. 2006, vol. 118, No. 4, pp. 1388-1393.
[cited by applicant]
Shepherd, E. L., et al., “Inhibition Of Vascular Adhesion Protein-1 Modifies Hepatic Steatosis In Vitro And In Vivo,” World Journal of Hepatology, Nov. 27, 2020, vol. 12, No. 11, pp. 931-948.
[cited by applicant]
Simone, J. V. (1996) “Introduction” in Cecil Textbook of Medicine. 20th Ed., vol. I . J. Claude Bennet and F. Plum (Eds.) W.B. Sauders Co.; pp. 1004-1010.
[cited by applicant]
Sinha, R. A. et al., “Direct Effects of Thyroid Hormones on Hepatic Lipid Metabolism,” Nat. Rev. Endocrinology, May 2018, 14(5):259-269 (26 total pages).
[cited by applicant]
Taub, R,, et al., ‘Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist,’ Atherosclerosis, 2013, 230:373-380.
[cited by applicant]
U.S. Appl. No. 17/305,302, filed Jul. 2, 2021, by Shanghai Yu et al. (The U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Vuppalanchi, R., et al., “Therapeutic pipeline in nonalcoholic steatohepatitis,” Nature Reviews Gastroenterology, Feb. 2021, vol. 18, No. 6, pp. 373-392, doi: 10.1038/S41575-020-00408-Y.
[cited by applicant]
Walenbergh, S. A., et al., “Cholesterol is a significant risk factor for nonalcoholic steatohepatitis,” Expert Review of Gastroenterology & Hepatology 2015, 9(11):1343-1346.
[cited by applicant]
Extended European Search Report and Search Opinion, dated Dec. 23, 2024, for European Patent Application No. 22764006.7, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability, mailed Nov. 28, 2024, for International Application No. PCT/US2023/022093, 6 pages.
[cited by applicant]